{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:11:37Z","timestamp":1772266297986,"version":"3.50.1"},"reference-count":49,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["WT097452MA"],"award-info":[{"award-number":["WT097452MA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106555\/Z\/14\/Z"],"award-info":[{"award-number":["106555\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A17341"],"award-info":[{"award-number":["A17341"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["WT107963AIA"],"award-info":[{"award-number":["WT107963AIA"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants. We demonstrate that BAP1 deubiquitinase activity and its association with ASXL1 to form the Polycomb repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism. Death receptor agonists are well-tolerated anti-cancer agents demonstrating limited therapeutic benefit in trials without a targeting biomarker. We identify\n                    <jats:italic>BAP1<\/jats:italic>\n                    loss-of-function mutations, which are frequent in MM, as a potential genomic stratification tool for TRAIL sensitivity with immediate and actionable therapeutic implications.\n                  <\/jats:p>","DOI":"10.7554\/elife.30224","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T05:00:48Z","timestamp":1516251648000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.30224","source":"Crossref","is-referenced-by-count":22,"title":["Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells"],"prefix":"10.7554","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3537-0231","authenticated-orcid":true,"given":"Krishna Kalyan","family":"Kolluri","sequence":"first","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-6696","authenticated-orcid":true,"given":"Constantine","family":"Alifrangis","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-2112","authenticated-orcid":true,"given":"Neelam","family":"Kumar","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Price","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-2277","authenticated-orcid":true,"given":"Magali","family":"Michaut","sequence":"additional","affiliation":[{"name":"The Netherlands Cancer Institute, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9382-4337","authenticated-orcid":true,"given":"Steven","family":"Williams","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syd","family":"Barthorpe","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Lightfoot","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Busacca","sequence":"additional","affiliation":[{"name":"CRUK Leicester Centre, Department of Cancer studies, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel","family":"Sharkey","sequence":"additional","affiliation":[{"name":"CRUK Leicester Centre, Department of Cancer studies, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-421X","authenticated-orcid":true,"given":"Elizabeth K","family":"Sage","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabarinath","family":"Vallath","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Le Quesne","sequence":"additional","affiliation":[{"name":"CRUK Leicester Centre, Department of Cancer studies, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Tice","sequence":"additional","affiliation":[{"name":"Oncology Research, MedImmune, Inc., Gaithersburg, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doraid","family":"Alrifai","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"von Karstedt","sequence":"additional","affiliation":[{"name":"Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Montinaro","sequence":"additional","affiliation":[{"name":"Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Guppy","sequence":"additional","affiliation":[{"name":"UCL Advanced Diagnostics, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Waller","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Nakas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Good","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Holmes","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Walczak","sequence":"additional","affiliation":[{"name":"Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A","family":"Fennell","sequence":"additional","affiliation":[{"name":"CRUK Leicester Centre, Department of Cancer studies, University of Leicester, Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Garnett","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Iorio","sequence":"additional","affiliation":[{"name":"European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[{"name":"The Netherlands Cancer Institute, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ultan","family":"McDermott","sequence":"additional","affiliation":[{"name":"Wellcome Trust Sanger Institute, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-5939","authenticated-orcid":true,"given":"Samuel M","family":"Janes","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, UCL Respiratory, University College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4374","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1172\/JCI80420","article-title":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions","volume":"125","author":"Ashkenazi","year":"2015","journal-title":"Journal of Clinical Investigation"},{"key":"bib3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nature Communications"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nature Genetics"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nature Genetics"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/onc.2015.213","article-title":"Resistance to HSP90 inhibition involving loss of MCL1 addiction","volume":"35","author":"Busacca","year":"2016","journal-title":"Oncogene"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"28643","DOI":"10.1074\/jbc.M115.661553","article-title":"The BAP1\/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer","volume":"290","author":"Daou","year":"2015","journal-title":"Journal of Biological Chemistry"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Research"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/cam4.137","article-title":"Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer","volume":"2","author":"Forero-Torres","year":"2013","journal-title":"Cancer Medicine"},{"key":"bib13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7120","article-title":"Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity","volume":"6","author":"Fujimoto","year":"2015","journal-title":"Nature Communications"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","article-title":"Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs","volume":"12","author":"Ganten","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/biostatistics\/kxp045","article-title":"PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data","volume":"11","author":"Greenman","year":"2010","journal-title":"Biostatistics"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Research"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2010.11.001","article-title":"Targeting Apo2L\/TRAIL receptors by soluble Apo2L\/TRAIL","volume":"332","author":"Holland","year":"2013","journal-title":"Cancer Letters"},{"key":"bib21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of affymetrix genechip probe level data","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Research"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Research"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1093\/nar\/gku274","article-title":"The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex","volume":"42","author":"Ji","year":"2014","journal-title":"Nucleic Acids Research"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nature Medicine"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/cdd.2013.179","article-title":"Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death and Differentiation"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death and Differentiation"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Molecular and Cellular Biology"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"Journal of Thoracic Oncology"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Human Pathology"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/cdd.2013.106","article-title":"Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells","volume":"20","author":"Passante","year":"2013","journal-title":"Cell Death and Differentiation"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/JTO.0b013e31827ce554","article-title":"A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer","volume":"8","author":"Paz-Ares","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nature Genetics"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/thoraxjnl-2015-207496","article-title":"MesobanK UK: an international mesothelioma bioresource","volume":"71","author":"Rintoul","year":"2016","journal-title":"Thorax"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Soria","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/bioinformatics\/btn577","article-title":"A novel signaling pathway impact analysis","volume":"25","author":"Tarca","year":"2009","journal-title":"Bioinformatics"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Research"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nature Reviews Cancer"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clinical Lung Cancer"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clcc.2013.06.002","article-title":"A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer","volume":"12","author":"Wainberg","year":"2013","journal-title":"Clinical Colorectal Cancer"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","article-title":"Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads","volume":"25","author":"Ye","year":"2009","journal-title":"Bioinformatics"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jcyt.2015.03.603","article-title":"Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy","volume":"17","author":"Yuan","year":"2015","journal-title":"Cytotherapy"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/30224\/elife-30224-v2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/30224\/elife-30224-v2.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/30224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:47:57Z","timestamp":1697057277000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/30224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":49,"alternative-id":["10.7554\/eLife.30224"],"URL":"https:\/\/doi.org\/10.7554\/elife.30224","archive":["CLOCKSS"],"relation":{"references":[{"id-type":"uri","id":"http:\/\/cancer.sanger.ac.uk\/cell_lines\/download","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.7554\/eLife.30224.031","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.30224.032","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]},"article-number":"e30224"}}